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DOI 10.1186/s13075-017-1406-xRESEARCH ARTICLE Open AccessEffects of HLA-DRB1 alleles on susceptibility
and clinical manifestations in Japanese
patients with adult onset Still’s disease
Tomoyuki Asano1, Hiroshi Furukawa2, Shuzo Sato1, Makiko Yashiro1, Hiroko Kobayashi1, Hiroshi Watanabe1,
Eiji Suzuki3, Tomoyuki Ito4, Yoshifumi Ubara5, Daisuke Kobayashi6, Nozomi Iwanaga7, Yasumori Izumi7,
Keita Fujikawa8, Satoshi Yamasaki9, Tadashi Nakamura10, Tomohiro Koga11, Toshimasa Shimizu11,
Masataka Umeda11, Fumiaki Nonaka12, Michio Yasunami13, Yukitaka Ueki14, Katsumi Eguchi14, Naoyuki Tsuchiya2,
Shigeto Tohma15, Koh-ichiro Yoshiura16, Hiromasa Ohira17, Atsushi Kawakami11 and Kiyoshi Migita1*Abstract
Background: HLA-DRB1 alleles are major determinants of genetic predisposition to rheumatic diseases. We assessed
whether DRB1 alleles are associated with susceptibility to particular clinical features of adult onset Still’s disease
(AOSD) in a Japanese population by determining the DRB1 allele distributions.
Methods: DRB1 genotyping of 96 patients with AOSD and 1,026 healthy controls was performed. Genomic DNA
samples from the AOSD patients were also genotyped for MEFV exons 1, 2, 3, and 10 by direct sequencing.
Results: In Japanese patients with AOSD, we observed a predisposing association of DRB1*15:01 (p = 8.60 × 10−6,
corrected p (Pc) = 0.0002, odds ratio (OR) = 3.04, 95% confidence interval (95% CI) = 1.91–4.84) and DR5 serological
group (p = 0.0006, OR = 2.39, 95% CI = 1.49–3.83) and a protective association of DRB1*09:01 (p = 0.0004, Pc = 0.0110,
OR = 0.34, 95% CI = 0.18–0.66) with AOSD, and amino acid residues 86 and 98 of the DRβ chain were protectively
associated with AOSD. MEFV variants were identified in 49 patients with AOSD (56.3%). The predisposing effect of
DR5 was confirmed only in patients with AOSD who had MEFV variants and not in those without MEFV variants.
Additionally, DR5 in patients with AOSD are associated with macrophage activation syndrome (MAS) and steroid
pulse therapy.
Conclusion: The DRB1*15:01 and DR5 are both associated with AOSD susceptibility in Japanese subjects. A
protective association between the DRB1*09:01 allele and AOSD was also observed in these patients. Our data
also highlight the effects of DRB1 alleles in susceptibility to AOSD.
Keywords: Adult onset Still’s disease, Autoinflammatory disease, Human leukocyte antigen, Macrophage-activation
syndrome, Systemic juvenile idiopathic arthritisBackground
Adult onset Still’s disease (AOSD), manifested by spiking
fever, skin rash, and arthritis, is a complex (multigenic)
autoinflammatory disease, meaning that its development
depends on a combination of genetic and environmental
risk factors [1]. The concept of autoinflammation ori-
ginally emerged from innate immune system activation* Correspondence: migita@fmu.ac.jp
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inflammatory disease, acquired autoinflammatory dis-
eases in which both innate and adaptive immune
abnormalities are implicated are more common [3]; this
group includes genetically complex rheumatic diseases,
such as AOSD [4]. Complex genetic factors may confer
susceptibility to AOSD development under certain en-
vironmental conditions [5].
The HLA cluster is one of the most intensively studied
genetic factors in AOSD [6]. HLA molecules are linked
with adaptive immunity, where they act to presentle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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[7]. Currently, there is no consensus on the relationship
between AOSD and HLA. Previous studies on the gen-
etic predisposition to AOSD have limitations and have
had inconsistent results [8]. This may be caused by the
small number of patients included in these studies, due
to the rarity of this disease and its heterogeneous clinical
manifestations.
Systemic juvenile idiopathic arthritis (sJIA) and AOSD
both manifest as systemic arthritis [9]. Recent studies
have provided new clues to the genetic underpinning of
sJIA. A genome-wide association study of sJIA identified
a strong association between sJIA and HLA-DRB1*11
[10]. This study supports a role for DRB1 alleles as a
major sJIA risk factor [10]. To determine whether or
not genetic variations of DRB1 alleles also influence
AOSD risk, we investigated the DRB1 alleles in Japanese
patients with AOSD. Previously, we found preliminary
evidence suggesting that familial Mediterranean fever
(FMF)-related MEFV variants can affect the disease
phenotype of AOSD [11]. In this study we evaluated
the influence of the MEFV genotype and HLA-DRB1
alleles on AOSD risk.
Methods
Design, setting, patients, and measurements
We retrospectively evaluated 96 patients (mean age ±
standard deviation = 50.2 ± 20.2 years, 78 female (81.2%)),
who had AOSD and were treated at the Department of
Rheumatology of the participating hospital group, between
2010 and 2017. The patients had all been diagnosed with
AOSD according to the Yamaguchi criteria [12], after
exclusion of infectious, hematologic, and autoimmune
diseases. Among 96 patients, 87 patients had undergone
laboratory tests, including a complete blood count, liver
function tests, urinalysis, erythrocyte sedimentation rate
(ESR), C-reactive protein (CRP) and ferritin. In the
remaining nine patients, the demographic and MEFV
genotyping data were not available except gender and age.
The clinical characteristics of these patients, including
age, gender, length of follow up, clinical features,
treatments, outcomes, and complications, were evalu-
ated using a standardized form. The study considered
three clinical AOSD courses: (1) monocyclic, defined
as a single episode that subsequently faded and was
followed by persistent good health for 1 year or more
of follow up; (2) polycyclic, defined as a complete re-
mission followed by one or more exacerbations; and
(3) chronic, defined as persistently active disease, usu-
ally associated with polyarthritis [13]. Complicated
AOSD was defined as including one or more of the
following conditions: liver dysfunction, disseminated
intravascular coagulation, and macrophage activation
syndrome (MAS) as defined previously [14]. Thisstudy was approved by the institutional review board
of the Sasebo City Hospital (number 2012-A-22) and
participating hospitals.
Genotyping methods
DRB1 allele typing was performed using a Luminex
200 system (Luminex, Austin, TX, USA) and a WAK-
Flow HLA Typing kit (Wakunaga, Hiroshima, Japan)
as described previously [15]. DRB1 alleles were assigned
automatically using WAKflow Typing software (Wakunaga).
The DR5 serological group consists of DRB1*11:01,
*12:01, and *12:02 [16]. Genotyping results for the
healthy controls (mean age ± standard deviation = 37.7
± 11.7 years, 303 male (29.8%)) were previously reported
[17].
MEFV gene analysis
Genomic DNA was extracted from whole blood using
the Promega Wizard® Genomic DNA Purification Kit
(Madison, WI, USA) according to the manufacturer’s
instructions. Polymerase chain reaction (PCR) was
performed using forward and reverse primers for each
exon of the MEFV gene, as described previously [18].
PCR was performed using the forward and reverse
primers for each exon (Additional file 1: Figure S1). The
resulting PCR products were purified using ExoSAP-IT
(GE Healthcare, Tokyo, Japan) and directly sequenced
using specific primers and BigDye Terminator v1.1 (Ap-
plied Biosystems, Tokyo, Japan). The MEFV genetic
analysis was approved by the Ethics Committee of
Fukushima Medical University School of Medicine
(2016, number 2920).
Statistical analysis
Differences among AOSD characteristics were analyzed
by performing the Mann-Whitney U test or chi-squared
test using 2 × 2 contingency tables. The association of al-
lele carrier frequencies, haplotype carrier frequencies or
amino acid residue carrier frequencies with AOSD was
analyzed using Fisher’s exact test with 2 × 2 contingency
tables under the dominant model. Adjustment for mul-
tiple comparisons was conducted with the Bonferroni
method; corrected p (Pc) values were calculated by
multiplying the p value by the number of tested alleles
or amino acid positions. To examine whether each
DRB1 allele independently contributes to AOSD, mul-
tiple logistic regression analysis under the additive model
was employed and the deviation from 0 was evaluated
for coefficients using the Wald test.
Results
Demographic findings of enrolled patients with AOSD
Clinical manifestations of the enrolled patients are
shown in Table 1. Among the 87 enrolled patients
Table 1 Demographics of AOSD patients
Variable Value
Number 87
Female, n (%) 69 (79.3)
Age at onset (years) 49.3 ± 19.9
Ferritin (ng/mL) 11251.2 ± 16997.9
CRP (mg/dL) 12.4 ± 8.2
ESR (mm(1 h)) 71.1 ± 30.1
Liver dysfunction, n (%) 68 (78.1)
MAS, n (%) 23 (26.4)
Initial dose of PSL (mg/day) 41.8 ± 12.2
Steroid pulse, n (%) 55 (63.2)
Immunosuppressant, n (%) 51 (58.6)
Biologics, n (%) 26 (29.8)
Polycyclic systemic type, n (%) 56 (64.3)
Monocyclic systemic type, n (%) 19 (21.8)
Chronic arthritis type, n (%) 12 (13.7)
Relapse, n (%) 40 (45.9)
Mean ± standard deviation or number (percentage) is shown
AOSD adult onset Still’s disease, CRP C-reactive protein, ESR erythrocyte
sedimentation rate, MAS macrophage activation syndrome, PSL prednisolone
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age at diagnosis was 49.3 ± 19.9 years. In terms of the
disease course, 56 patients (64.3%) had the polycyclic
systemic type, 19 (21.8%) had the monocyclic systemic
type, and 12 (13.7%) had the chronic articular type of
AOSD (Table 1).
Association of specific DRB1 alleles with AOSD
Associations of specific DRB1 alleles with AOSD were
evaluated in a case-control study consisting of the 96
Japanese patients with AOSD as described previously
and 1026 healthy subjects (Table 2). The patients with
AOSD had significantly higher frequencies of the
DRB1*15:01 allele (p = 8.60 × 10−6, corrected p (Pc) =
0.0002, odds ratio (OR) = 3.04, 95% confidence interval
(95% CI) = 1.91–4.84) compared with healthy subjects.
Although patients with AOSD appeared to have higher
frequencies of DRB1*12:01 allele than healthy subjects,
this difference was not statistically significant. However,
an association between DR5 serological group and AOSD
was observed.
Reduced DRB1*09:01 allele carrier frequencies in AOSD
In contrast to the predisposing effects of the DRB1*15:01
allele, DRB1*09:01 was negatively associated with AOSD
(Table 2). In fact, although the DRB1*15:01 allele pre-
disposed individuals to AOSD in the absence of
DRB1*09:01, the DRB1*15:01 allele was not associated
with AOSD in those carrying the DRB1*09:01 allele
(Table 3). Thus, the protective effects of DRB1*09:01can neutralize the AOSD-predisposing effects of the
DRB1*15:01 allele. When the allele carrier frequencies
of DRB1 alleles in patients with AOSD were compared
with age-matched healthy controls, a similar associative
tendency was observed (Additional file 2: Table S1). In
addition, conditional logistic regression analysis be-
tween age, gender, DRB1*09:01, DRB1*15:01, and DR5
in AOSD was performed (Additional file 3: Table S2).
The association of DRB1*09:01, DRB1*15:01, and DR5
remained significant, when conditioned on age or gen-
der, and these were independent of each other.
MEFV variant analysis
All patients with AOSD were successfully genotyped
for the MEFV gene. MEFV variants were identified in
49 patients with AOSD (56.3%), and the distributions
of MEFV variants in the patients are shown in Table 4.
We stratified the patients with AOSD according to the
presence of MEFV variants. The predisposing effect of
DRB1*15:01 on AOSD development was not changed
by the presence or absence of MEFV variants (Table 5).
In contrast, the AOSD-predisposing effect of DR5 was
confirmed in patients with AOSD with MEFV variants,
but DR5 was not associated with AOSD in patients
without MEFV variants. Thus, the presence or absence
of MEFV variants can affect the AOSD-predisposing
effects of DR5.
Association of specific DRB1 alleles and clinical
manifestations of AOSD
To evaluate the potential correlation between DRB1
alleles and the clinical manifestations of AOSD, we
stratified the patients with AOSD according to the
presence of the DRB1*15:01 allele (Table 6). There was
no significant difference in the clinical manifestations,
including the disease phenotype, between patients with
AOSD with and without the DRB1*15:01 allele. We
then compared the clinical manifestations between pa-
tients with AOSD with or without DR5. Patients with
AOSD with DR5 more frequently have macrophage ac-
tivation syndrome (MAS) and are more frequently
treated by steroid pulse therapy than those without
DR5 (Table 6).
Amino acid residues in the HLA-DRβ chain are protect-
ively associated with AOSD
We also analyzed the association between amino acid
residues in the HLA-DRβ chain and AOSD. Glycine at
position 86 (86G, p = 7.88 × 10-7, OR = 0.24, Pc = 2.68 ×
10-5, 95% CI 0.15–0.41) and glutamic acid at position
98 (98E, p = 2.80 × 10-5, OR = 0.40, Pc = 0.0010, 95% CI
0.26–0.62) in the DRβ chain showed a protective asso-
ciation with AOSD (Fig. 1, open circle).
Table 2 HLA-DRB1 allele carrier frequency in the patients with AOSD and in controls
Cases (n = 96) Controls (n = 1026) P OR Pc 95% CI
DRB1*01:01 9 (9.4) 110 (10.7) 0.8622 0.86 NS (0.42–1.76)
DRB1*03:01 0 (0.0) 3 (0.3) 1.0000 1.52 NS (0.08–29.55)
DRB1*04:01 0 (0.0) 22 (2.1) 0.2486 0.23 NS (0.01–3.84)
DRB1*04:03 4 (4.2) 47 (4.6) 1.0000 0.91 NS (0.32–2.57)
DRB1*04:04 0 (0.0) 4 (0.4) 1.0000 1.18 NS (0.06–22.03)
DRB1*04:05 21 (21.9) 243 (23.7) 0.8014 0.90 NS (0.54–1.49)
DRB1*04:06 2 (2.1) 76 (7.4) 0.0562 0.27 NS (0.06–1.10)
DRB1*04:07 0 (0.0) 15 (1.5) 0.6313 0.34 NS (0.02–5.70)
DRB1*04:10 4 (4.2) 32 (3.1) 0.5413 1.35 NS (0.47–3.90)
DRB1*07:01 0 (0.0) 9 (0.9) 1.0000 0.55 NS (0.03–9.61)
DRB1*08:02 13 (13.5) 72 (7.0) 0.0403 2.08 NS (1.10–3.90)
DRB1*08:03 16 (16.7) 153 (14.9) 0.6544 1.14 NS (0.65–2.01)
DRB1*08:09 0 (0.0) 2 (0.2) 1.0000 2.12 NS (0.10–44.55)
DRB1*09:01 11 (11.5) 280 (27.3) 0.0004 0.34 0.0110 (0.18–0.66)
DRB1*10:01 0 (0.0) 5 (0.5) 1.0000 0.96 NS (0.05–17.54)
DRB1*11:01 6 (6.3) 41 (4.0) 0.2837 1.60 NS (0.66–3.87)
DRB1*12:01 16 (16.7) 75 (7.3) 0.0031 2.54 0.0896 (1.41–4.56)
DRB1*12:02 8 (8.3) 37 (3.6) 0.0488 2.43 NS (1.10–5.38)
DRB1*13:01 2 (2.1) 8 (0.8) 0.2082 2.71 NS (0.57–12.93)
DRB1*13:02 5 (5.2) 163 (15.9) 0.0040 0.29 0.1150 (0.12–0.73)
DRB1*14:03 7 (7.3) 44 (4.3) 0.1941 1.76 NS (0.77–4.01)
DRB1*14:04 0 (0.0) 4 (0.4) 1.0000 1.18 NS (0.06–22.03)
DRB1*14:05 6 (6.3) 40 (3.9) 0.2758 1.64 NS (0.68–3.98)
DRB1*14:06 2 (2.1) 29 (2.8) 1.0000 0.73 NS (0.17–3.11)
DRB1*14:07 0 (0.0) 2 (0.2) 1.0000 2.12 NS (0.10–44.55)
DRB1*14:54 6 (6.3) 58 (5.7) 0.8168 1.11 NS (0.47–2.65)
DRB1*15:01 31 (32.3) 139 (13.5) 8.60 × 10-6 3.04 0.0002 (1.91–4.84)
DRB1*15:02 18 (18.8) 224 (21.8) 0.5197 0.83 NS (0.48–1.41)
DRB1*16:02 0 (0.0) 18 (1.8) 0.3919 0.28 NS (0.02–4.72)
DR5(*11, *12) 28 (29.2) 151 (14.7) 0.0006 2.39 (1.49–3.83)
Allele carrier frequencies are shown in parentheses (%). Association was tested by Fisher’s exact test using 2 × 2 contingency tables under the dominant model.
AOSD adult onset Still’s disease, OR odds ratio, CI confidence interval, Pc corrected p value, NS not significant
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AOSD is an inflammatory disorder of uncertain etiology
characterized by spiking fever, rash, and arthritis that is
accompanied by high ferritin levels [19]. Both sJIA and
AOSD are considered to be autoinflammatory diseasesTable 3 HLA-DRB1 genotype frequencies in the patients with AOSD
Cases (n = 96) Control
*15:01/any alleles 31 (32.3) 139 (13
*15:01/*09:01 1 (1.0) 21 (2.0)
*15:01/alleles other than *09:01 30 (31.3) 118 (11
Genotype frequencies are shown in parentheses (%). Association was tested by Fish
OR odds ratio, CI confidence intervalwith a dysregulated innate immune system [20]. However,
this characterization is limited by the fact that dysfunc-
tions of the innate and adaptive immune systems are
not mutually exclusive, even in monogenic forms of
autoinflammatory disease [21].and in controls
s (n = 1026) P OR 95% CI
.5) 8.60 × 10-6 3.04 (1.91-4.84)
1.0000 0.50
.5) 1.64 × 10-6 3.50 (2.18-5.61)
er’s exact test using 2 × 2 contingency tables. AOSD adult onset Still’s disease,
Table 4 MEFV genotypes of patients with AOSD
Mutations Number of patients
(percentage) (n = 87)
M694I/normal 2 (2.3)
G632S/E408Q 1 (1.1)
P369S/R408Q 4 (4.6)
E148Q/P369S 1 (1.1)
E148Q/E148Q/P369S/R408Q 1 (1.1)
L110P/E148Q/E148Q/P369S/R408Q 1 (1.1)
E148Q/P369S/R408Q 2 (2.3)
E148Q/R202Q 1 (1.1)
R202Q/normal 3 (3.4)
E148Q/normal 19 (21.8)
E148Q/E148Q 2 (2.3)
L110P/E148Q 6 (6.9)
L110P/E148Q//E148Q 2 (2.3)
L110P/E148Q//R202Q 1 (1.1)
L110P/L110P/E148Q//E148Q 1 (1.1)
E84K/normal 1 (1.1)
E84K/L110P/E148Q 1 (1.1)
Normal 38 (43.7)
AOSD adult onset Still’s disease
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disposition to rheumatic diseases [22]. Although no heredi-
tary trend has been reported in AOSD, some studies have
reported the associations between HLA-DR and AOSD.
Pouchot et al. described a strong association between
AOSD and HLA-DR2 [23]. Wouters et al. found an associ-
ation between DRB1*04 and AOSD and reported that DR6
(DRB1*13, *14) was more frequent in cases with axial joint
involvement [24]. Miller et al. reported a frequent associ-
ation between AOSD and HLA-DR7 [6]. Fujii et al. evalu-
ated the major histocompatibility complex (MHC) class II
alleles in 30 Japanese patients with AOSD and reported
that DRB1*15:01 and DRB1*12:01 were more frequently
detected in subjects with chronic articular forms of AOSD
than in healthy controls [25]. Additionally, a Korean study
showed that patients with AOSD more frequently had
DRB1*12 and *15, and less frequently had DRB1*04 than
control subjects [26]. However, controversies remain on
the association between HLA-DR molecules and AOSD.Table 5 HLA-DRB1 allele carrier frequency in the patients with AOSD
AOSD with
MEFV variants
AOSD without
MEFV variants
Controls AOSD
variant
(n = 49) (n = 38) (n = 1026) P
DRB1*15:01 17 (34.7) 13 (34.2) 139 (13.5) 0.0002
DR5(DRB1*11, *12) 16 (32.7) 8 (21.1) 151 (14.7) 0.0019
Allele carrier frequencies are shown in parentheses (%). Association was tested by F
AOSD adult onset Still’s disease, OR odds ratio, CI confidence interval, Pc corrected pRecent studies have provided new clues to the genetic
predispositions for developing systemic arthritis. A
genome-wide association study of sJIA patients identi-
fied a strong association between sJIA and DRB1*11
[10]. Interestingly, Ombrello et al. raised the new idea
that the MHC may act not as an antigen-presenting
molecule but rather as a direct activator of MHC class-
expressing macrophages or dendritic cells [10]. Our data
show that both DRB1*15:01 and DR5 are associated with
AOSD in Japanese patients. DRB1*15:01 is the HLA al-
lele that was most strongly associated with AOSD in our
study, and these results are consistent with those of pre-
vious studies in Japanese or Korean patients [25, 26].
Conversely, the DRB1*09:01 allele had a significantly
deceased frequency in patients with AOSD when compared
with that in control subjects as reported in multiple scler-
osis [27, 28]. However, this negative association of AOSD
with the DRB1*09:01 allele needs to be confirmed in the
other ethnic populations because the distribution of HLA
alleles is different between Japanese and other ethnic
populations. Notably, extensive heterogeneity is observed
in the clinical manifestations of AOSD, suggesting that
AOSD may actually be a heterogeneous subset of
disorders [29]. Our results suggest that DRB1 alleles
may play a role in the occurrence of AOSD; however,
it is possible that there are transcriptional changes for
other HLA loci that are co-inherited with DRB1, and
these haplotypes may also contribute to the AOSD
risk.
It was found that amino acid residues 86 and 98 of the
DRβ chain were protectively associated with AOSD
(Fig. 1). The DRB1*09:01 allele includes these two amino
acid residues, suggesting the predominant protective ef-
fects of DRB1*09:01 on AOSD. Amino acid residues 85,
86, 89, and 90 form the HLA-DR peptide-binding groove
for peptide position 1 [30], suggesting the involvement
of peptide antigens bound to the specific HLA-DR
molecule to prevent AOSD.
MEFV variants are commonly found in the Japanese
population [31]. Although the significance of MEFV
variants is controversial, some studies have suggested that
they can influence the phenotypes of inflammatory disor-
ders [32]. Here, we found that the DR5-associated risk for
AOSD was not detected in Japanese Patients with AOSD
without MEFV variants, whereas the DR5-associated riskwith or without MEFV variants
with MEFV
s vs. controls
AOSD without MEFV
variants vs. controls
OR Pc 95% CI P OR Pc 95% CI
3.39 0.0068 (1.83–6.27) 0.0013 3.32 0.0388 (1.66–6.64)
2.81 (1.51–5.23) 0.2543 1.55 (0.70–3.43)
isher’s exact test using 2 × 2 contingency tables under the dominant model.
value, NS not significant
Table 6 Comparison of the demographics between patients with AOSD with or without DRB1*15:01 or DR5
DRB1*15:01 (+) DRB1*15:01 (-) P DR5 (+) DR5 (-) P
Number 29 58 23 64
Female, n (%) 24 (82.7) 45 (77.5) 0.7789 20 (86.9) 49 (77.4) 0.2912
Age at onset (years) 46.6 ± 20.3 50.6 ± 19.6 0.3980 50.6 ± 20.5 48.1 ± 19.7 0.7469
Ferritin (ng/mL) 12818.5 ± 18292.9 10555.5 ± 16284.7 0.3657 12669.4 ± 16305.9 10802.9 ± 17224.9 0.3243
CRP (mg/dL) 11.9 ± 8.2 12.7 ± 8.3 0.6802 12.0 ± 9.2 12.6 ± 7.9 0.5068
ESR (mm(1 h)) 59.6 ± 25.3 75.4 ± 30.9 0.1289 67.4 ± 23.0 72.5 ± 32.5 0.9361
Liver dysfunction, n (%) 24 (82.7) 44 (75.8) 0.4630 19 (82.6) 49 (76.5) 0.5472
MAS, n (%) 10 (38.6) 13 (22.4) 0.2288 10 (43.4) 13 (20.3) 0.0307
Initial dose of PSL (mg/day) 43.8 ± 13.0 41.5 ± 11.7 0.4379 46.1 ± 10.9 40.3 ± 12.4 0.1184
Steroid pulse, n (%) 17 (58.6) 38 (65.5) 0.4987 19 (82.6) 36 (56.2) 0.0245
Immunosuppressant, n (%) 18 (57.6) 33 (56.8) 0.6442 15 (65.2) 36 (56.2) 0.4539
Biologics, n (%) 10 (38.6) 16 (27.5) 0.5077 6 (26.0) 20 (31.2) 0.6427
Polycyclic systemic type, n (%) 20 (68.9) 36 (62.0) 0.5266 18 (78.2) 38 (59.3) 0.1048
Monocyclic systemic type, n (%) 8 (27.5) 13 (22.4) 0.5951 4 (17.3) 17 (26.5) 0.3780
Chronic arthritis type, n (%) 4 (13.7) 8 (13.7) 1.0000 2 (8.6) 10 (15.6) 0.4085
Relapse, n (%) 14 (48.2) 26 (44.8) 0.7619 11 (47.8) 29 (45.3) 0.8357
Association was tested between patients with adult onset Still’s disease (AOSD) with or without DRB1*15:01 or DR5 analyzed by the chi-squared test using 2 × 2
contingency tables or the Mann-Whitney U test. CRP C-reactive protein, ESR erythrocyte sedimentation rate, MAS macrophage activation syndrome, PSL prednisolone
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variants. These finding suggest a possible interaction be-
tween DRB1 and MEFV in AOSD development or in the
AOSD disease phenotype. Furthermore, these findings
imply that differences between susceptible and non-
susceptible DR5 alleles are complemented by MEFV var-
iants in Japanese patients with AOSD, which could be
explained by the broad involvement of pyrin, the MEFV
encoded protein, in the regulation of the inflammasome
and inflammatory processes.Fig. 1 Association between amino acid residues in the DRβ chain
and adult onset Still’s disease. Differences in amino acid residue
carrier frequencies were analyzed by Fisher’s exact test using 2 × 2
contingency tables. Corrected p (Pc) values were calculated by
multiplying the p value by the number of amino acid residues
tested. Predisposing association is indicated by filled circles and
protective association by open circlesRheumatic diseases are likely on the spectrum between
autoimmunity and autoinflammation [33]. It was sug-
gested that a pathogenic model in which autoinflamma-
tory processes beget an autoimmune condition, sJIA, is a
prototype of AOSD [34]. A genome-wide association
study on sJIA identified a strong association between
sJIA and DRB1*11 alleles. DR5 is a broad-antigen sero-
type that is further split into HLA-DR11, which includes
DRB1*11:01, and HLA-DR12 [17]. In our study, patients
with DR5 were more frequently associated with AOSD
with macrophage activation syndrome (MAS), which has
some similarities to the clinical features of sJIA. These
findings are consistent with the reports by Ombrello
et al. that demonstrate an association between sJIA and
DRB1*11 alleles [11]. From a pathogenic point of view,
most autoinflammatory and autoimmune diseases share
a chronic aberrant activation of the immune system,
which leads to tissue inflammation and/or damage [35].].
In contrast to autoimmune diseases, “autoinflammatory
diseases” present with inflammation in the absence of
either high-titer autoantibodies or autoreactive T cells.
Although the evidence for autoimmunity in AOSD is
scant, there are some data that support a role for T cells
in its pathogenesis [36]. Additionally, class II HLA mole-
cules have a role in innate immunity and in the regulation
of macrophages, including antigen-presenting cells. For
example, super-antigen-engaged antigen-presenting cells
induce proinflammatory cytokines [37].
There are limitations in our study. Control subjects
were younger than the patients. AOSD is a rare disorder
Asano et al. Arthritis Research & Therapy  (2017) 19:199 Page 7 of 8offsetting any potential bias due to development of AOSD
later in life by a younger control. Another limitation is
that all of our study subjects were Japanese because too
few patients from other racial/ethnic backgrounds were
available for analysis. Also, the number of patients with
AOSD was modest and a larger study would be needed.
Conclusion
Our study provides evidence that DRB1*15:01 and DR5
confer a risk for AOSD. A protective association between
the DRB1*09:01 allele and AOSD was also observed in this
study. Specifically, our data demonstrate that DR5 is asso-
ciated with AOSD complicated with MAS, in a Japanese
population. Additional studies are needed to determine
the specific mechanism through which the HLA-DRB1
influences the risk of AOSD.
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